Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitorsinhibitor response.

Type 2 diabetes mellitus (T2DM) is a complex metabolic disease characterized by hyperglycaemia. T2DM is a highly heterogeneous polygenic disease. Due to genetic variation, variations in lifestyle and other environmental exposures, there are certain variations in the phenotype of T2DM patients. Sodium glucose cotransporter 2 (SGLT2) inhibitors are novel hypoglycaemic agents that increase urinary glucose excretion by inhibiting glucose reabsorption in the proximal tubules of the kidney. For glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, studies have confirmed a variety of gene variants that may modify their effects. For SGLT2 inhibitors, research has focused on the SLC5A2 gene encoding SGLT2 and UGT1A9 gene polymorphisms affecting SGLT2 inhibitor metabolism. The SLC5A2 polymorphism rs9934336 have been associated with decreased HbA1c during the oral glucose tolerance test. Common variants of the SLC5A2 gene are related to blood glucose and insulin concentrations, but not glucagon concentrations. SLC5A2 rs9934336 and rs3116150 are related to a lower risk of heart failure. SGLT2 inhibitor exposure of UGT1A9*3 carriers is commonly higher than that of noncarriers, while these effects commonly have no obvious clinical significance on SGLT2 inhibitor pharmacokinetics. In terms of efficacy, general SLC5A2 variants show no significant effect on the response to the SGLT2 inhibitor empagliflozin. At present, research on the relationship between genetic polymorphisms and the efficacy of SGLT2 inhibitors is limited. The main purpose of this review is to elucidate the general effects of SGLT2 polymorphisms and the association between polymorphisms and the treatment response to SGLT2 inhibitors.

An investigation of the intention and reasons of senior high school students in China to choose medical school.

BACKGROUND: Shortages of qualified health workers have been a global concern, especially in developing countries. China also faces this dilemma, which hinders the development of public health services. Senior high school students are a group who are considering their college majors and careers after graduation. They are also a potential and basic talent reserve for the health sector. This survey focused on senior high school students' intention to learn clinical medicine and explored potential influencing factors. METHODS: An anonymous questionnaire containing 20 items was distributed to 5344 senior high school students. The questions covered the following topics: students' intention to learn clinical medicine, personal and family information, understanding of medical education, cognition of doctors' working conditions, and doctor-patient relationships. Logistic regression and the chi-square test were used to compare students with and without a clear intention to learn clinical medicine to explore influencing factors. RESULTS: Only 5.6% of senior high school students had a clear intention to learn medicine (CILCM). Personal and family information had distinct impacts. Interest and anatomy course were also associated with students' choice. There was a positive correlation between understanding of medical education and students' intention Meanwhile, students' cognition of doctors, career prospects, and social status had significant impacts. The more optimistic students were about doctors' working conditions and doctor-patient relationships, the more likely they were to have a CILCM. CONCLUSION: To some extent, this survey reflects the shortage of medical talent in China and provides possible clues for solving this problem. In addition, these findings may provide a perspective for understanding the development of health services in developing countries.

Exploring the multifaceted role of RASGRP1 in disease: immune, neural, metabolic, and oncogenic perspectives.

RAS guanyl releasing protein 1 (RASGRP1) is a guanine nucleotide exchange factor (GEF) characterized by the presence of a RAS superfamily GEF domain. It functions as a diacylglycerol (DAG)-regulated nucleotide exchange factor, specifically activating RAS through the exchange of bound GDP for GTP. Activation of RAS by RASGRP1 has a wide range of downstream effects at the cellular level. Thus, it is not surprising that many diseases are associated with RASGRP1 disorders. Here, we present an overview of the structure and function of RASGRP1, its crucial role in the development, expression, and regulation of immune cells, and its involvement in various signaling pathways. This review comprehensively explores the relationship between RASGRP1 and various diseases, elucidates the underlying molecular mechanisms of RASGRP1 in each disease, and identifies potential therapeutic targets. This study provides novel insights into the role of RASGRP1 in insulin secretion and highlights its potential as a therapeutic target for diabetes. The limitations and challenges associated with studying RASGRP1 in disease are also discussed.

Fair classification via domain adaptation: A dual adversarial learning approach.

Modern machine learning (ML) models are becoming increasingly popular and are widely used in decision-making systems. However, studies have shown critical issues of ML discrimination and unfairness, which hinder their adoption on high-stake applications. Recent research on fair classifiers has drawn significant attention to developing effective algorithms to achieve fairness and good classification performance. Despite the great success of these fairness-aware machine learning models, most of the existing models require sensitive attributes to pre-process the data, regularize the model learning or post-process the prediction to have fair predictions. However, sensitive attributes are often incomplete or even unavailable due to privacy, legal or regulation restrictions. Though we lack the sensitive attribute for training a fair model in the target domain, there might exist a similar domain that has sensitive attributes. Thus, it is important to exploit auxiliary information from a similar domain to help improve fair classification in the target domain. Therefore, in this paper, we study a novel problem of exploring domain adaptation for fair classification. We propose a new framework that can learn to adapt the sensitive attributes from a source domain for fair classification in the target domain. Extensive experiments on real-world datasets illustrate the effectiveness of the proposed model for fair classification, even when no sensitive attributes are available in the target domain.

Formations of mixed-valence oxovanadiumV,IV citrates and homocitrate with N-heterocycle chelated ligand.

Dimeric mixed-valence oxovanadium citrate [V 2O 3(phen) 3(Hcit)].5H 2O ( 1) (H 4cit = citric acid, phen = 1,10-phenanthroline) was isolated from a weak acidic medium. It could be converted quantitatively into a tetrameric oxovanadium citrate adduct of 1,10-phenanthroline [V 2O 3(phen) 3(Hcit) 2(phen) 3O 3V 2].12H 2O ( 2). This was supported by the trace of infrared spectra and X-ray diffraction patterns. The two compounds feature a bidentate citrate group that chelates only to one vanadium center through their negatively charged alpha-alkoxy and alpha-carboxy oxygen atoms, while the other beta-carboxy and beta-carboxylic acid groups are free to participate in strong intramolecular and intermolecular hydrogen bonding [2.45(1) in 1 and 2.487(2) A in 2], respectively. This is also the case of homocitrato vanadate(V/IV) [V 2O 3(phen) 3( R, S-H 2homocit)]Cl.6H 2O ( 3) (H 4homocit = homocitric acid), which features a binding mode similar to that found in the R-homocitrato iron molybdenum cofactor of Mo-nitrogenase. Moreover, the homocitrato vanadate(V) [VO 2(phen) 2] 2[V 2O 4( R,S-H 2homocit) 2].4H 2O.2C 2H 5OH ( 4) is isolated as a molecular precursor for the formation of mixed-valence complex 3. The V-O alpha-alkoxy and V-O alpha-carboxy bond distances of homocitrate complexes 3 and 4 are 1.858(4) and 1.968(6) av and 2.085(4) and 1.937(5) A, respectively. They are shorter than those of homocitrate to FeVco (2.15 A). The gamma-carboxy groups of coordinated homocitrato complexes 3 and 4, and the free homocitrate salt Na 3(Hhomocit).H 2O ( 5), form strong hydrogen bonds with the chloride ion and the water molecule [2.982(5) in 3, 2.562(9) in 4, and 2.763(1) A in 5], respectively.

α-Hydroxy coordination of mononuclear vanadyl citrate, malate and S-citramalate with N-heterocycle ligand, implying a new protonation pathway of iron-vanadium cofactor in nitrogenase.

Unlike the most of α-alkoxy coordination in α-hydroxycarboxylates to vanadium, novel α-hydroxy coordination to vanadium(IV) has been observed for a series of chiral and achiral monomeric α-hydroxycarboxylato vanadyl complexes [VO(H2cit)(bpy)]·2H2O (1), [VO(Hmal)(bpy)]·H2O (2), [VO(H2cit)(phen)]·1.5H2O (3), [VO(Hmal)(phen)]·H2O (4), and [(Δ)VO(S-Hcitmal)(bpy)]·2H2O (5), [VO(H2cit)(phen)]2·6.5H2O (6), which were isolated from the reactions of vanadyl sulfate with α-hydroxycarboxylates and N-heterocycle ligands in acidic solution. The complexes feature a tridentate citrate, malate or citramalate that chelates to vanadium atom through their α-hydroxy, α-carboxy and ß-carboxy groups; while the other ß-carboxylic acidic group of citrate is free to participate strong hydrogen bonds with lattice water molecule. The neutral α-hydroxy group also forms strong intermolecular hydrogen bonds with water molecule and the negatively-charged α-carboxy group in the environment. The inclusion of a hydrogen ion in α-alkoxy group results in the formation of a series of neutral complexes with one less positive charge. There are two different configurations of citrate with respect to the trans-position of axial oxo group, where the complex with trans-hydroxy configuration seems more stable with less hindrance. The average bond distances of V-Ohydroxy and V-Oα-carboxy are 2.196 and 2.003Å respectively, which are comparable to the VO distance (2.15Å) of homocitrate in FeV-cofactor of V-nitrogenase. A new structural model is suggested for R-homocitrato iron vanadium cofactor as VFe7S9C(R-Hhomocit) (H4homocit=homocitric acid) with one more proton in homocitrate ligand.

N-heterocycle chelated oxomolybdenum(VI and V) complexes with bidentate citrate.

A 1,10-phenanthroline (phen) chelated molybdenum(VI) citrate, [(MoO2)2O(H2cit)(phen)(H2O)2] x H2O (1) (H4cit = citric acid), is isolated from the reaction of citric acid, ammonium molybdate and phen in acidic media (pH 0.5-1.0). A citrato oxomolybdenum(V) complex, [(MoO)2O(H2cit)2(bpy)2] x 4H2O (2), is synthesized by the reduction of citrato molybdate with hydrazine hydrochloride in the presence of 2,2'-bipyridine (bpy), and a monomeric molybdenum(VI) citrate [MoO2(H2cit)(bpy)] x H2O (6) is also isolated and characterized structurally. The citrate ligand in the three neutral compounds uses the alpha-alkoxy and alpha-carboxy groups to chelate as a bidentate leaving the two beta-carboxylic acid groups free, that is different from the tridentate chelated mode in the citrato molybdate(VI and V) complexes. 1 and in solution show obvious dissociation based on 13C NMR studies.